Visterra is dedicated to the discovery and development of innovative products for the prevention, treatment and diagnosis of infectious diseases. Visterra utilizes an integrated technology platform, built around its unique structural understanding of the role of glycans (complex sugars) in infectious disease, to rationally design drug candidates which are both more effective and refractory to resistance development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/25/12 | $13,000,000 | |||
| 11/09/12 | $13,000,000 | Series A |
Bill & Melinda Gates Foundation Flagship Ventures Lux Capital Omega Funds Polaris Partners | undisclosed |
| 12/02/13 | $8,100,000 | Series A-2 |
Bill & Melinda Gates Foundation Flagship Ventures Lux Capital Omega Funds Polaris Partners | undisclosed |
| 10/02/14 | $30,000,000 | Series B |
Alexandria Real Estate Equities Cycad Group Flagship Ventures Merck Research Labs Venture Fund Omega Funds Polaris Partners Temasek Vertex Ventures | undisclosed |
| 10/05/17 | $46,700,000 | Series C |
Alexandria Venture Investments Allegheny Financial Group Bill & Melinda Gates Foundation CTI Life Sciences Cycad Group Flagship Pioneering MRL Ventures Fund Omega Funds Polaris Partners Serum Institute of India | undisclosed |
